Literature DB >> 21271265

Intraventricular craniopharyngioma: morphological analysis and outcome evaluation of 17 cases.

Jun Pan1, Songtao Qi, Yuntao Lu, Jun Fan, Xi'an Zhang, Jie Zhou, Junxiang Peng.   

Abstract

PURPOSE: There is still some confusion with regard to the tumor-third ventricle floor (3rd VF) relationship of craniopharyngiomas located exclusively within the third ventricle. This study aims to provide some evidence to clarify the growth pattern of intraventricular craniopharyngiomas (IVC), and to summarize the surgical strategy and outcome.
METHODS: Seventeen cases of IVC were reviewed retrospectively in relation to preoperative imaging, clinical presentation, intraoperative findings, tumor pathology, and surgical outcome. The tumor-3rd VF relationship and the tumor's stratification were analyzed based on intraoperative inspection and histology.
FINDINGS: Variable adherence patterns of IVC to the 3rd VF were found, which were classified as (a) purely IVC with pedicle attachment to 3rd VF (two cases), (b) intra-3rd VF tumors with wide-based attachment but a dissectible tumor boundary (seven cases), and (c) intra-3rd VF tumors with an undissectible wide, tight attachment (eight cases). Histological analysis revealed that both of the two cases with growth pattern "a" intruded into the third ventricular cavity without a covering layer of neural tissue (which only exists in the squamous-papillary subtype). Tumors with growth pattern "b" and "c," in contrast, were noted to have a thin layer of neural tissue. This occurred in both subtypes (11 adamantinomatous, 4 papillary). Total removal was accomplished in all tumors demonstrating growth pattern "a" and "b." There was also better preservation of the 3rd VF and consequently a better outcome. On the other hand, total removal was only achieved in 50% of tumors showing growth pattern "c" including one mortality. No recurrence has been encountered in patients whose tumors were totally removed.
CONCLUSION: Variable adherence patterns and tumor subtypes were observed in IVCs, which were correlated to the tumor pathology, resectability, and subsequent prognosis.

Entities:  

Mesh:

Year:  2011        PMID: 21271265     DOI: 10.1007/s00701-010-0938-5

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  7 in total

1.  Hypothalamus-referenced classification for craniopharyngiomas: evidence provided by the endoscopic endonasal approach.

Authors:  José M Pascual; Ruth Prieto; Ines Castro Dufourny; Ricardo Gil Simoes; Rodrigo Carrasco
Journal:  Neurosurg Rev       Date:  2012-12-16       Impact factor: 3.042

2.  Freiburg Neuropathology Case Conference : Tumor Located in the Anterior Portion of the Third Ventricle.

Authors:  C A Taschner; P Süß; M Hohenhaus; H Urbach; N Lützen; M Prinz
Journal:  Clin Neuroradiol       Date:  2018-03       Impact factor: 3.649

3.  Clinical impact of craniopharyngioma classification based on location origin: a multicenter retrospective study.

Authors:  Wenfu Hu; Binghui Qiu; Fen Mei; Jian Mao; Lizhi Zhou; Fan Liu; Jun Fan; Yi Liu; Ge Wen; Songtao Qi; Yun Bao; Jun Pan
Journal:  Ann Transl Med       Date:  2021-07

Review 4.  Craniopharyngioma adherence: a reappraisal of the evidence.

Authors:  Ruth Prieto; José María Pascual; Verena Hofecker; Eduard Winter; Inés Castro-Dufourny; Rodrigo Carrasco; Laura Barrios
Journal:  Neurosurg Rev       Date:  2018-07-24       Impact factor: 3.042

5.  Craniopharyngioma and the Third Ventricle: This Inescapable Topographical Relationship.

Authors:  José María Pascual; Ruth Prieto
Journal:  Front Oncol       Date:  2022-03-22       Impact factor: 6.244

Review 6.  Neuroendoscopic resection of intraventricular tumors: a systematic outcomes analysis.

Authors:  Sean M Barber; Leonardo Rangel-Castilla; David Baskin
Journal:  Minim Invasive Surg       Date:  2013-09-26

7.  Intrinsic Third Ventricular Papillary Craniopharyngioma: A Report of Five Cases and Literature Review.

Authors:  Nguyen Duy Hung; Nguyen Minh Duc; Vuong Kim Ngan
Journal:  Int Med Case Rep J       Date:  2021-02-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.